柴芪汤对非酒精性脂肪肝大鼠固醇调节元件结合蛋白-1c表达的影响

目的:观察柴芪汤对非酒精性脂肪性肝病(NAFLD)大鼠肝脏固醇调节元件结合蛋白-1c(SREBP-1c)m RNA及蛋白表达的影响,探讨其防治NAFLD的可能机制。方法:将32只SPF级雄性SD大鼠随机分为正常组、模型组、柴芪汤组和罗格列酮组,每组8只,采用高脂高糖高盐饮食喂养8周复制NAFLD模型,造模第一天开始用药,给予柴芪汤5.67g/(kg·d)]及罗格列酮混悬液3 mg/(kg·d)]灌胃干预,8周后检测大鼠血清丙氨酸氨基转移酶(ALT)、天冬氨酸转氨酶(AST)、甘油三酯(TG)、胆固醇(TC)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)及肝组织中TG含量;观察肝组织病理形态改变;Western Blot测定肝SREBP-1c蛋白表达;RT-PCR测定肝SREBP-1c m RNA表达。结果:模型组大鼠血清ALT、AST、TC、TG、HDL-C、LDL-C水平及肝组织中TG含量明显高于正常组(P0.05),2用药组各项指标低于模型组,差异有统计学意义(P0.05);但2组间比较,差异无统计学意义(P0.05)。2用药组SREBP-1c m RNA及蛋白表达水平较模型组降低,差异具有统计学意义(P0.05),但2用药组比较差异无统计学意义(P0.05)。结论:柴芪汤能够改善NAFLD大鼠肝脏脂肪变,其干预效果与西药罗格列酮相似,抑制SREBP-1c m RNA和蛋白表达,从而降低NAFLD大鼠血清ALT、AST、TG、TC、HLD-C、LDL-C,这可能是柴芪汤治疗NAFLD的机制之一。

Effects of ChaiQi Tang on Expression of SREBP-1c in Rats with Nonalcoholic Fatty Liver Disease

Objective:To observe the effects of ChaiQi Tang on SREBP-1c mRNA and protein expression in rats with nonalcoholic fatty liver disease (NAFLD) and explore the possible mechanism of preventing and treating NAFLD.Methods:All 32 male SPF rats were randomly divided into the normal group,the model group,ChaiQi Tang group and rosiglitazone group,each group eight rats,all groups were fed with high salt,high fat and high sugar diet for eight weeks for duplicating NAFLD model,the medication groups accepted gastric lavage of ChaiQi Tang 5.67 g/(kg·d)] and rosiglitazone suspension 3 mg/(kg·d)] from the fast day of preparing the models,ALT,AST,TG,TC,HDL-C,LDL-C and TG level in liver were detected after eight weeks;pathological changes of hepatic tissue were observed;SREBP-1c protein expression was measured by Western Blot;SREBP-1c mRNA expression was measured by RT-PCR.Results:The model group was higher than the normal group obviously in the levels of ALT,AST,TG,TC,HDL-C,LDL-C in serum and TG in liver (P＜0.05),the two medication groups were lower than the model group in different indexes,and there were statistical differences (P＜0.05);there were no statistical difference between two groups (P＞0.05).Two medication groups were lower than the model group in the levels of SREBP-1c mRNA and protein expression,there were statistical differences (P＜0.05),but there were no statistical differences between two medication groups (P＞0.05).Conclusion:ChaiQi Tang can improve fatty change of liver in rats with NAFLD,its intervention function is similar to rosiglitazone,ChaiQi Tang also can inhibit SREBP-lc mRNA and protein expression,finally reducing ALT,AST,TG,TC,HDL-C,LDL-C of serum in rats with NAFLD,this may be one of mechanisms of ChaiQi Tang treating NAFLD.